TABLE 3.
Characteristics of 200 patients commencing hepatitis C treatment in prison in three large Health Board areas, 2009–2012
| Patient characteristics | All patients N (%) | Completed treatment, n (row %)
|
Achieved SVR, n (row %)
|
||||
|---|---|---|---|---|---|---|---|
| Yes | No/not knowna | P valuec | Yes (n=131) | No/not knownb (n=69) | P valuec | ||
| All patients | 200 (100%) | 147 (74%) | 53 (27%) | – | 131 (66%) | 69 (35%) | – |
| Aged | |||||||
| 20–29 years | 28 (14%) | 21 (75%) | 7 (25%) | – | 21 (75%) | 7 (25%) | – |
| 30–39 years | 103 (52%) | 79 (77%) | 24 (23%) | .85 | 64 (62%) | 39 (38%) | .21 |
| >40 years | 66 (33%) | 47 (71%) | 19 (29%) | .71 | 45 (68%) | 21 (32%) | .51 |
| Not known | 3 (2%) | 0 (0%) | 3 (100%) | – | 1 (33%) | 2 (67%) | – |
| Sex | |||||||
| Male | 173 (87%) | 126 (73%) | 47 (27%) | – | 113 (65%) | 60 (35%) | – |
| Female | 27 (14%) | 21 (78%) | 6 (22%) | .54 | 18 (67%) | 9 (33%) | .89 |
| Major HCV genotype | |||||||
| 1 or 4 | 77 (39%) | 49 (64%) | 28 (36%) | – | 41 (53%) | 36 (47%) | – |
| 2 or 3 | 123 (62%) | 98 (80%) | 25 (20%) | .01 | 90 (73%) | 33 (27%) | <.01 |
| Cirrhosisd | |||||||
| Yes | 7 (4%) | 3 (43%) | 4 (57%) | – | 3 (43%) | 4 (57%) | – |
| No | 193 (97%) | 144 (75%) | 49 (25%) | .08 | 128 (66%) | 65 (34%) | 0.22 |
| Baseline viral load | |||||||
| Low | 133 (67%) | 101 (76%) | 32 (24%) | – | 91 (68%) | 42 (32%) | – |
| High | 61 (31%) | 43 (70%) | 18 (30%) | .42 | 36 (59%) | 25 (41%) | .20 |
| Not known | 6 (3%) | 3 (50%) | 3 (50%) | – | 4 (67%) | 2 (33%) | – |
| Drug injecting history | |||||||
| Within last one year | 48 (24%) | 34 (71%) | 14 (29%) | – | 32 (67%) | 16 (33%) | – |
| More than one year ago | 132 (66%) | 103 (78%) | 29 (22%) | .32 | 88 (67%) | 44 (33%) | 1.00 |
| Never/unknown | 20 (10%) | 10 (50%) | 10 (50%) | – | 11 (55%) | 9 (45%) | – |
| Opiate replacement | |||||||
| Yes | 98 (49%) | 72 (74%) | 26 (27%) | – | 69 (70%) | 29 (30%) | – |
| No | 30 (15%) | 24 (80%) | 6 (20%) | .47 | 22 (73%) | 8 (27%) | .76 |
| Not known | 72 (36%) | 51 (71%) | 21 (29%) | – | 40 (56%) | 32 (44%) | – |
| Treatment intentionse | |||||||
| Intention to complete in prison | 128 (64%) | 109 (85%) | 19 (15%) | – | 94 (73%) | 34 (27%) | – |
| Intention to complete in community | 38 (19%) | 12 (32%) | 26 (68%) | <.01 | 16 (42%) | 22 (58%) | <.01 |
| Not known | 34 (17%) | 26 (76%) | 8 (24%) | – | 21 (62%) | 13 (38%) | – |
| Prison sentence | |||||||
| <4 years | 131 (66%) | 96 (73%) | 35 (27%) | – | 84 (64%) | 47 (36%) | – |
| ≥4 years | 42 (21%) | 33 (79%) | 9 (21%) | .49 | 30 (71%) | 12 (29%) | .39 |
| Not known | 27 (14%) | 18 (67%) | 9 (33%) | – | 17 (63%) | 10 (37%) | – |
| Movement during treatment | |||||||
| None | 125 (63%) | 107 (86%) | 18 (14%) | – | 92 (74%) | 33 (26%) | – |
| Transferred but not released | 37 (19%) | 26 (70%) | 11 (30%) | .04 | 22 (59%) | 15 (41%) | .10 |
| Released (+/− transfer) | 38 (19%) | 14 (37%) | 24 (63%) | <.01 | 17 (45%) | 21 (55%) | <.01 |
|
| |||||||
| Patients with GT 1/4 | 77 (100%) | 49 (64%) | 28 (36%) | – | 41 (53%) | 36 (47%) | – |
| Released during HCV treatment | |||||||
| No | 56 (72%) | 42 (75%) | 14 (25%) | – | 34 (61%) | 22 (39%) | – |
| Yes | 21 (27%) | 7 (33%) | 14 (67%) | <.01 | 7 (33%) | 14 (67%) | .03 |
|
| |||||||
| Patients with GT 2/3 | 123 (100%) | 98 (80%) | 25 (20%) | – | 90 (73%) | 33 (27%) | – |
| Released during HCV treatment | |||||||
| No | 106 (86%) | 91 (86%) | 15 (14%) | – | 80 (75%) | 26 (25%) | – |
| Yes | 17 (14%) | 7 (41%) | 10 (59%) | <.01 | 10 (59%) | 7 (41%) | .15 |
a
Treatment completion status not known for 18 (9%) cases.
b
Treatment outcome not known for 42 (21%) cases.
c
P value refers to comparison between proportion “yes” and proportion “no/not known”. P values in bold type denote statistical significance at P <0.1.
d
At treatment commencement.
e
“intention-to-complete treatment in prison” was not included in the multivariate model, due to correlation with “released during treatment”.
f
Variable collapsed due to cell sizes <5.